Yu Danyang, Zeng Xinyi, Barzilai David, Thor Dominik, Lyu Yu-Xuan
Sirio Institute for Anti-Ageing (SIA), Sirio Life Technology Co., Ltd, Shanghai, 201703, China.
Geneva College of Longevity Science, 1204, Geneva, Switzerland.
Biogerontology. 2025 Jul 1;26(4):138. doi: 10.1007/s10522-025-10278-z.
The field of longevity interventions has witnessed rapid expansion, driven by scientific advancements alongside growing industry and consumer interest. However, no longevity intervention has yet been proven effective or ready for widespread clinical adoption. A substantial gap persists between public expectations and the current scientific realities. This article explores four key themes: (1) consumer priorities regarding longevity interventions, (2) the type and depth of scientific information they value, (3) psychological, financial, and practical barriers limiting adoption, and (4) potential strategies to overcome these challenges. Despite increasing enthusiasm, clinical translation of longevity research is constrained by the lack of validated interventions, regulatory frameworks, and standardized biomarkers. By distinguishing between scientifically supported and unproven approaches, this article proposes a roadmap outlining the critical milestones necessary to advance longevity interventions from research to clinical readiness. The goal is to realign public understanding with the current state of longevity science and guide future efforts toward safe and effective translation.
在科学进步以及行业和消费者兴趣不断增长的推动下，长寿干预领域迅速扩张。然而，尚无任何长寿干预措施被证明有效或准备好广泛应用于临床。公众期望与当前科学现实之间仍存在巨大差距。本文探讨了四个关键主题：（1）消费者对长寿干预的优先考虑事项，（2）他们重视的科学信息的类型和深度，（3）限制采用的心理、财务和实际障碍，以及（4）克服这些挑战的潜在策略。尽管热情日益高涨，但长寿研究的临床转化受到缺乏经过验证的干预措施、监管框架和标准化生物标志物的制约。通过区分科学支持的方法和未经证实的方法，本文提出了一个路线图，概述了将长寿干预从研究推进到临床应用所需的关键里程碑。目标是使公众的理解与长寿科学的现状重新对齐，并指导未来朝着安全有效的转化方向做出努力。
